Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garyphallia Poulakou

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|October 1, 2011
Pharmacokinetic and pharmacodynamic evaluation of tigecyclineHelen Giamarellou, Garyphallia Poulakou
Expert Opinion on Investigational Drugs|May 2, 2008
Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogensGaryphallia Poulakou, Helen Giamarellou
Drugs|September 15, 2009
Multidrug-resistant Gram-negative infections: what are the treatment options?Helen Giamarellou, Garyphallia Poulakou
Intensive Care Medicine|October 13, 2016
Planet's population on the move, infections on the riseGaryphallia Poulakou, Diamantis Plachouras
Expert Opinion on Investigational Drugs|January 31, 2008
Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogensGaryphallia Poulakou, Helen Giamarellou
Expert Opinion on Investigational Drugs|January 25, 2007
Investigational treatments for postoperative surgical site infectionsGaryphallia Poulakou, Helen Giamarellou
Current Opinion in Infectious Diseases|January 22, 2019
What's new in the epidemiology of skin and soft tissue infections in 2018?Garyphallia Poulakou, Styliani Lagou, Sotirios Tsiodras
Current Opinion in Infectious Diseases|January 31, 2017
What is new in the management of skin and soft tissue infections in 2016?Garyphallia Poulakou, Efthymia Giannitsioti, Sotirios Tsiodras
Microorganisms|January 21, 2022
Emerging and Re-Emerging Infectious Diseases: Humankind's Companions and CompetitorsNikolaos Spernovasilis, Sotirios Tsiodras, Garyphallia Poulakou
Critical Care Medicine|September 17, 2015
"Excess Mortality" and Colistin-Tigecycline for Extensively Drug-Resistant Acinetobacter baumannii BacteremiaGaryphallia Poulakou, Matteo Bassetti, Sotirios Tsiodras
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Expert Opinion on Drug Metabolism & Toxicology|October 1, 2011
Pharmacokinetic and pharmacodynamic evaluation of tigecyclineHelen Giamarellou, Garyphallia Poulakou
Expert Opinion on Investigational Drugs|May 2, 2008
Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogensGaryphallia Poulakou, Helen Giamarellou
Drugs|September 15, 2009
Multidrug-resistant Gram-negative infections: what are the treatment options?Helen Giamarellou, Garyphallia Poulakou
Intensive Care Medicine|October 13, 2016
Planet's population on the move, infections on the riseGaryphallia Poulakou, Diamantis Plachouras
Expert Opinion on Investigational Drugs|January 31, 2008
Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogensGaryphallia Poulakou, Helen Giamarellou
Expert Opinion on Investigational Drugs|January 25, 2007
Investigational treatments for postoperative surgical site infectionsGaryphallia Poulakou, Helen Giamarellou
Current Opinion in Infectious Diseases|January 22, 2019
What's new in the epidemiology of skin and soft tissue infections in 2018?Garyphallia Poulakou, Styliani Lagou, Sotirios Tsiodras
Current Opinion in Infectious Diseases|January 31, 2017
What is new in the management of skin and soft tissue infections in 2016?Garyphallia Poulakou, Efthymia Giannitsioti, Sotirios Tsiodras
Microorganisms|January 21, 2022
Emerging and Re-Emerging Infectious Diseases: Humankind's Companions and CompetitorsNikolaos Spernovasilis, Sotirios Tsiodras, Garyphallia Poulakou
Critical Care Medicine|September 17, 2015
"Excess Mortality" and Colistin-Tigecycline for Extensively Drug-Resistant Acinetobacter baumannii BacteremiaGaryphallia Poulakou, Matteo Bassetti, Sotirios Tsiodras
Pageof 9